Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Radiopharmaceutical-focused VC deals in US see staggering 550% growth to $408 million in 2023, reveals GlobalData

The US radiopharmaceutical drugs space saw a 550% increase in total deal value of venture capital (VC) deals, from $63 million in 2017 to $408 million in 2023 year to date (YTD), reveals GlobalData, a leading data and analytics company. Radiopharmaceutical drugs integrate radioisotopes into drugs or monoclonal antibodies, enabling precise tumor detection through nuclear […]
Read more

Ammonia and methanol set to lead decarbonization in petrochemical sector, says GlobalData

Ammonia and methanol are key industrial chemicals with strong demand in agriculture, manufacturing, and construction sectors. Conventional ammonia and methanol production processes contribute to carbon emissions. As governments around the world are pursuing various decarbonization strategies, it has become imperative to curb emissions from these processes. The evolution of low-carbon hydrogen, a critical feedstock for […]
Read more

ICC Men’s Cricket World Cup 2023 success marred by fan discontent and logistical challenges, reveals GlobalData

The 2023 ICC Men’s Cricket World Cup held in India between 5 October and 19 November witnessed unprecedented success with record-breaking attendance and viewership. Despite this achievement, the event left fans disappointed due to a disorganized ticketing process and high prices. The contrast between the event’s popularity and the challenges faced by fans highlights the […]
Read more

GlobalData highlights transformative impact of AR/VR technologies in construction industry

The construction industry is on the brink of a profound shift with the integration of augmented and virtual reality (AR/VR) technologies. These advancements promise a radical redefinition of design, planning, and execution in construction projects. The collaborative potential of these technologies extends to project management, safety training, and customer issue resolution, showcasing a transformative trajectory […]
Read more

Microsoft, Nordea Bank find themselves at opposite ends of market value spectrum in 2023, reveals GlobalData

Microsoft and Nordea Bank experienced contrasting market fortunes in 2023. While the Redmond-based tech giant gained the most market value, the Finland-based banking company registered the biggest loss, reveals the Company Profiles Database of GlobalData, a leading data and analytics company Microsoft has reportedly gained a whopping $1 trillion to reach a market cap $2.8 […]
Read more

Environmental aspects weigh heavily in ESG-related discussions by companies, finds GlobalData

Under mounting pressure from regulators and investors, businesses worldwide across sectors have been progressively embracing environmental, social, and governance (ESG) frameworks. Against this backdrop, companies are discussing ESG extensively in their filing documents, with a particular emphasis on the significant influence of environmental aspects, according to GlobalData, a leading data and analytics company. Misa Singh, […]
Read more

Ad withdrawals spur 100% surge in discussions around advertising for X Corp, observes GlobalData

Walmart is the latest company to suspend advertising on “X” (formerly Twitter). The US-based retail giant joins several prominent brands, including Apple, Sony, IBM and Disney, to withdraw advertising on the social media platform, in response to Elon Musk’s endorsement of an antisemitic conspiracy theory in November. Several other companies too are reportedly contemplating to […]
Read more

Non-stimulants face uphill battle to penetrate ADHD market despite lower abuse potential, observes GlobalData

Stimulants, amphetamines, and methylphenidates continue to dominate the attention deficit hyperactivity disorder (ADHD) market across the seven major markets (7MM*), serving as the primary pharmacological treatment. Despite historical hesitancy towards their use in children, recent safety reassurances have increased acceptance. The late-stage pipeline introduces non-stimulant options with a focus on lower abuse potential. However, penetrating […]
Read more

Psychedelic drug partnerships surge 500% in 2023, signaling potential in mental health therapeutics, reveals GlobalData

The landscape of psychedelic drug development has witnessed a remarkable surge in recent years, with a 500% increase in partnership deals from 2019 to 2023. More than 40 collaborations since 2019 have propelled the exploration of innovative psychedelics like psilocybin and LSD, showcasing their potential in addressing conditions such as depression and anxiety. Despite regulatory […]
Read more

Pharma contract manufacturing sees historic surge amidst inflation and investment challenges, reveals GlobalData

In the dynamic landscape of pharmaceutical contract manufacturing, the year 2022 witnessed unprecedented growth in revenues, marking the highest surge since 2011. The total commercial dose contract manufacturing organization (CMO) contract revenue year-on-year (YoY) soared by an impressive 8.4% in 2022. This growth, fueled by persistent high inflation, occurred amid the waning demand for COVID-19 […]
Read more

More than 25,000 job postings for ESG roles across each quarter since 2022, says GlobalData

As organizations transition towards increasingly sustainable and socially responsible business methodologies, they recognize the imperative to engage professionals adept at addressing and navigating environmental, social, and governance (ESG) challenges. Consequently, companies spanning various sectors are consistently posting ESG* roles, with each quarter since 2022 seeing more than 25,000 job postings from around 8,000 recruiters, reveals […]
Read more

AbbVie’s $10.1 billion Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge, says GlobalData

Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 billion; Israel Stern, MSc,  Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “The news comes one day after AbbVie announced that it is preparing to […]
Read more
1 … 82 83 84 85 86 … 209